<p>Subjects were divided approximately in tertiles: baseline PCSK9<40 ng/mL, 40 to <60 ng/mL, or ≥60 ng/mL; change in LDL cholesterol from baseline <30%, 30 to <50%, or ≥50%.</p
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secreted inhibitor of the low-density lip...
Abstract Background During the past decade, proprotein convertase subtilisin kexin type 9 (PCSK9) ha...
Rations of simvastatin for 24 hours at 37°C. 50 μg of total cell lysates (A and C) and 100 μl cell m...
Therapy with PCSK9 inhibitors resulted in an overall LDL cholesterol reduction of 40%. As can be see...
<p>(A) Correlation between baseline PCSK9 concentrations (log-transformed) and percent change in PCS...
<p>Data are means ± SEM. The decrease in LDL cholesterol was significant in all groups (all <i>P</i>...
BACKGROUND: Although statin therapy is known to in-crease concentrations of PCSK9, whether this effe...
<p>Values are means ± SDs, Spearman’s correlation coefficients <i>rho</i> between baseline plasma PC...
BACKGROUND: Although statin therapy is known to in-crease concentrations of PCSK9, whether this effe...
<p>Study subjects classified according to status as carriers of c.−3383C>G <i>PCSK9</i> and c.*52G>A...
Ds. Pre-treatment levels were set as 100%.<p><b>Copyright information:</b></p><p>Taken from "Plasma ...
International audienceI n order to assess the risk of cardiovascular diseases in patients, fasting p...
Ds. Pre-treatment levels were set as 100%.<p><b>Copyright information:</b></p><p>Taken from "Plasma ...
S. Pre-treatment levels were set as 100%.<p><b>Copyright information:</b></p><p>Taken from "Plasma P...
type 9 (PCSK9) is a protein convertase that posttrans-lationally promotes the degradation of the low...
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secreted inhibitor of the low-density lip...
Abstract Background During the past decade, proprotein convertase subtilisin kexin type 9 (PCSK9) ha...
Rations of simvastatin for 24 hours at 37°C. 50 μg of total cell lysates (A and C) and 100 μl cell m...
Therapy with PCSK9 inhibitors resulted in an overall LDL cholesterol reduction of 40%. As can be see...
<p>(A) Correlation between baseline PCSK9 concentrations (log-transformed) and percent change in PCS...
<p>Data are means ± SEM. The decrease in LDL cholesterol was significant in all groups (all <i>P</i>...
BACKGROUND: Although statin therapy is known to in-crease concentrations of PCSK9, whether this effe...
<p>Values are means ± SDs, Spearman’s correlation coefficients <i>rho</i> between baseline plasma PC...
BACKGROUND: Although statin therapy is known to in-crease concentrations of PCSK9, whether this effe...
<p>Study subjects classified according to status as carriers of c.−3383C>G <i>PCSK9</i> and c.*52G>A...
Ds. Pre-treatment levels were set as 100%.<p><b>Copyright information:</b></p><p>Taken from "Plasma ...
International audienceI n order to assess the risk of cardiovascular diseases in patients, fasting p...
Ds. Pre-treatment levels were set as 100%.<p><b>Copyright information:</b></p><p>Taken from "Plasma ...
S. Pre-treatment levels were set as 100%.<p><b>Copyright information:</b></p><p>Taken from "Plasma P...
type 9 (PCSK9) is a protein convertase that posttrans-lationally promotes the degradation of the low...
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secreted inhibitor of the low-density lip...
Abstract Background During the past decade, proprotein convertase subtilisin kexin type 9 (PCSK9) ha...
Rations of simvastatin for 24 hours at 37°C. 50 μg of total cell lysates (A and C) and 100 μl cell m...
DOI
Add to ORKG